|1.||Devereux, Richard B: 111 articles (12/2015 - 02/2002)|
|2.||Dahlöf, Björn: 108 articles (12/2015 - 02/2002)|
|3.||Wachtell, Kristian: 77 articles (12/2015 - 02/2002)|
|4.||Kjeldsen, Sverre E: 71 articles (12/2015 - 03/2002)|
|5.||Nieminen, Markku S: 56 articles (11/2015 - 03/2002)|
|6.||Okin, Peter M: 50 articles (12/2015 - 01/2003)|
|7.||Ibsen, Hans: 50 articles (12/2015 - 03/2002)|
|8.||Gerdts, Eva: 44 articles (11/2015 - 02/2002)|
|9.||Lindholm, Lars H: 40 articles (12/2015 - 03/2002)|
|10.||Julius, Stevo: 34 articles (07/2014 - 03/2002)|
|1.||Hypertension (High Blood Pressure)
09/01/2001 - "Losartan treatment induced a significant reduction in basal pressure but did not interfere with the development of hypertension (similar pressure increases of 24% and 28% over control values in losartan and vehicle groups, respectively). "
01/01/1995 - "Our data indicate that losartan induced a significant reduction in MAP in patients with essential arterial hypertension with only moderate effects on renal hemodynamics."
01/01/2002 - "The results of our study suggest that losartan is effective in reducing blood pressure only at rest but is unable to improve exercise BP response or cardiac performance in subjects with mild-to-moderate essential hypertension."
06/01/1997 - "Losartan is effective in the treatment of essential hypertension and has a low incidence of adverse effects. "
01/01/1997 - "Once daily administration of losartan 50 to 100 mg is an effective treatment for patients with essential mild to moderate hypertension. "
07/01/2004 - "In case 2, losartan with steroid and immunosuppressant led to the complete remission of proteinuria, improvement of renal dysfunction and reduction of the glomerular injury score from repeat biopsy specimen by approximately 20%. "
01/01/2004 - "Proteinuria reduction was significantly greater in patients receiving combined therapy in comparison with losartan treatment after 3 months of therapy (p = 0.02). "
12/01/2015 - "In this study, we investigated the molecule mechanisms of podocyte injury and proteinuria and the protective effects of losartan. "
03/01/2005 - "This post hoc analysis examined whether baseline proteinuria was predictive of cardiovascular outcomes, and whether losartan modifies the risk of cardiovascular outcomes in these patients given its renal-protective effects. "
04/01/2009 - "Short-term losartan treatment, besides antihypertensive effect, improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria. "
11/01/2003 - "Losartan attenuated the renal vasoconstrictor response to a significantly greater degree in congestive heart failure than in control rats. "
01/01/1997 - "Recent clinical trial data indicate that losartan may also be beneficial in heart failure in older patients, though the drug is not yet approved for this indication."
11/01/2012 - "There have been no mortality/morbidity endpoint studies with losartan in Chinese heart failure patients. "
04/11/2012 - "Results from observational studies suggest that losartan may be associated with increased mortality in patients with heart failure compared with other ARBs. "
02/01/2010 - "Patients with heart failure randomized to high-dose losartan treatment (150 mg) in the HEAAL study had a reduced risk of death or heart failure hospitalization compared with patients in the low-dose (50 mg) group. "
09/01/2013 - "Treatment with losartan resulted in a significant reduction in left atrial fibrosis and AF duration (P<.01). "
05/01/2012 - "Losartan treatment was associated with significant impressive improvement in muscle strength and amelioration of fibrosis. "
01/01/2012 - "Twenty-one days after induction, losartan significantly improved the macro- and microscopic scores of fibrosis in the colonic wall and reduced TGF-b1 concentration. "
05/11/2011 - "We demonstrated that mice treated with losartan developed significantly less fibrosis and exhibited improved in vivo muscle function after cardiotoxin-induced injury. "
12/15/2015 - "In histopathological findings and serum biochemistry analyses, chronic losartan administration showed muscular protective effects and inhibited fibrosis in skeletal (gastrocnemius), cardiac, and diaphragmatic muscles. "
11/01/1996 - "In SHR-SP, losartan prevented stroke and improved the cerebral artery's smooth muscle and endothelial cell functions, which are altered during ageing and impaired even more dramatically by stroke occurrence."
09/01/2004 - "Among the ARBs, losartan possesses certain unique properties not shared by other members of its class, which enhance its stroke-protective effects. "
06/01/2001 - "Losartan was subsequently shown to decrease central venous pressure and wedge pressure, while cardiac output, left ventricle stroke work and stroke volume all showed improvement. "
11/01/1996 - "Whereas all control SHR-SP had died within 18 weeks of being born, losartan at both doses afforded full protection against stroke and mortality. "
02/01/2007 - "Sub-analyses of the LIFE study data suggest that losartan's stroke benefit may arise from a mosaic of mechanisms rather than a single action. "
|7.||Angiotensin Receptors (Angiotensin II Receptor)
|9.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
|2.||Transplantation (Transplant Recipients)
|5.||Renal Dialysis (Hemodialysis)